Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Mediterranean Diet Correlates With Responses to Melanoma ImmunotherapyFebruary 28th 2023
Previous research has identified a link between nutrients commonly found in a Mediterranean diet such as fiber, unsaturated fats, antioxidants, and polyphenols, and immunomodulatory/anti-tumor activities, according to a dietician from the University of Groningen.
Glasgow Prognostic Score May Predict Atezolizumab/Chemo Outcomes in SCLCFebruary 22nd 2023
A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Nivolumab Combo Yields PFS Benefit Regardless of PD-L1, c-MET status in RCCFebruary 21st 2023
An ongoing exploratory biomarker analysis of the CheckMate 9ER trial set out to identify predictive biomarkers or a composite model of response of nivolumab/cabozantinib efficacy in advanced renal cell carcinoma.
Brexu-cel Yields Consistent Efficacy in R/R Mantle Cell Lymphoma in SOC SettingFebruary 20th 2023
Prior exposure to recent bendamustine and having tumor-intrinsic features were associated with inferior efficacy outcomes following treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma.
Trilaciclib Reduces Neutropenia but Fails to Improve ORR in Metastatic CRCFebruary 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.
Bendamustine/Rituximab Appears Tolerable in Geriatric Mantle Cell LymphomaFebruary 9th 2023
Real-world findings from an observational study indicate that bendamustine plus rituximab appears to be well tolerated by elderly patients with transplant-ineligible mantle cell lymphoma and indolent non-Hodgkin lymphoma.
SBRT Provides Positive Locoregional Control in Lung Neuroendocrine TumorsFebruary 9th 2023
Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.
Atezolizumab Plus Bevacizumab Shows Potential in TMB-H Nonsquamous NSCLCFebruary 7th 2023
Findings from the phase 2 TELMA trial suggest that atezolizumab plus bevacizumab yields robust, long-lasting outcomes for patients with metastatic nonsquamous tumor mutational burden–high non–small cell lung cancer.